QNRX Quoin Pharmaceuticals Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671502
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-142.5%
ROA-95.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.00x
Current ratio7.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $0 |
| R&D expense | $9.80M | $3.60M | $3.31M | $2.67M | $1.56M |
| SG&A expense | $6.49M | $5.93M | $6.07M | $6.58M | $4.50M |
| Interest expense | — | — | — | — | $1.09M |
| Pretax income | -$15.80M | -$8.96M | — | — | — |
| Net income | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -$21.46M |
| EPS (basic) | — | — | — | — | -0.01 |
| EPS (diluted) | — | — | — | — | -0.01 |
| Weighted avg. shares (diluted) | — | — | — | — | 1.58B |
| Balance sheet | |||||
| Cash & equivalents | $3.82M | $3.62M | $2.40M | $2.86M | $7.48M |
| Short-term investments | $14.93M | $10.43M | — | — | — |
| Current assets | $20.01M | $14.93M | $11.29M | $13.37M | $8.20M |
| Intangibles | $383,334 | $483,334 | $583,334 | $704,561 | $808,604 |
| Total assets | $20.39M | $15.71M | $12.17M | $14.46M | $9.36M |
| Current liabilities | $5.55M | $4.18M | $3.58M | $3.53M | $4.58M |
| Total liabilities | $7.27M | $6.50M | $6.51M | $7.05M | $8.70M |
| Shareholders' equity | $13.12M | $9.20M | $5.66M | $7.41M | $657,032 |
| Shares outstanding | 52.44M | 8.95M | 987,220 | 403,887 | 3.35B |
| Cash flow statement | |||||
| Operating cash flow | -$13.54M | -$7.86M | -$7.86M | -$8.48M | -$5.72M |
| Investing cash flow | -$4.28M | -$1.89M | $2.19M | -$10.15M | -$625,000 |
| Financing cash flow | $18.01M | $10.97M | $5.22M | $14.01M | $13.50M |
| Stock-based compensation | $1.15M | $1.26M | $1.09M | $764,007 | $0 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.